The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

A TEENAGE girl has died from a brain-swelling bat virus which experts fear could be the ‘next pandemic’. The 18-year-old tested positive for Nipah virus, an extremely lethal disease ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

On Monday, the Iowa Department of Health and Human Services announced the seventh case of measles in the state.

Lockheed Reports Earnings at a Tough Time. Drones and Defense Budgets Are a Worry. For the quarter, Wall Street is looking for earnings per share of about $6.41 from sales of $18.5 billion, according ...

From daycare outbreaks to the dreaded mouth sores, here's what parents need to know about hand, foot, and mouth disease.

"So, when your immune system is challenged, let's say you get a flu shot or COVID ... effect against the cancers produced by EBV." Antiviral treatment can "inhibit" virus reactivation, Schang said, ...

KeyBanc's John Vinh reiterated his Overweight rating for the stock and reaffirmed his $240 target price. GM Earnings Are Coming. Tariffs, EV Tax Credits-and What It Means for the Stock ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.